Drugs / Dysport (R)
Dysport (R)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03805152 Comparator | Oct 2019 → Jan 2021 | cervical dystonia | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dysport (R) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03805152 ↗ |
| Known as | abo-BoNT/A | “Abobotulinum neurotoxin type A, abo-BoNT/A, (Dysport®) is the most potent biological toxin produced from Clostridium botulinum.” NCT03805152 ↗ |
| Known as | Abobotulinum neurotoxin type A | “Abobotulinum neurotoxin type A, abo-BoNT/A, (Dysport®) is the most potent biological toxin produced from Clostridium botulinum.” NCT03805152 ↗ |
| Known as | Dysport | “Abobotulinum neurotoxin type A, abo-BoNT/A, (Dysport®) is the most potent biological toxin produced from Clostridium botulinum.” NCT03805152 ↗ |
| Modality | Protein / enzyme biologic | “Abobotulinum neurotoxin type A, abo-BoNT/A, (Dysport®) is the most potent biological toxin produced from Clostridium botulinum.” NCT03805152 ↗ |
| Route | Intramuscular | “250 unit Intramuscular Injection” NCT03805152 ↗ |